Bronchial thermoplasty is a non-drug treatment for asthma and is currently under clinical investigation. Bronchial thermoplasty is an investigational procedure in which precisely controlled thermal energy is delivered with a tiny catheter to targeted airway walls of patients with asthma. This procedure is intended to reduce muscle in the walls of airways, and thereby decrease the ability of airways to narrow in patients with symptomatic asthma... Asthmatx's Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
March
(46)
- Masimo Rainbow SET Pulse CO-Oximetry Effective as ...
- Lilly : US$4.4 Million to the WHO for MDR-TB Progr...
- Nereus Pharmaceuticals : Clinical Trail of NPI-235...
- Masimo : Schiller AG Adopts its Rainbow SET as The...
- Accuray : CyberKnife Radiosurgery Used to Treat Lu...
- Actavis : approval of generic Wellbutrin SR and Zy...
- Merck Statement on the FDA Early Communication of ...
- Kamada : Advancement in its Phase II Trial with Ae...
- EpiCept, Myriad Genetics, Azixa
- Poniard Pharmaceuticals : Additional data presenta...
- AstraZeneca : Phase III Studies Of The Investigati...
- SPO Medical : Shipping PulseOx 6000(TM) and PulseO...
- MicroDose Technologies : Global License to Merck &...
- Mpex Pharmaceuticals : MP-376, Granted U.S. Orphan...
- Arriva Pharmaceuticals : Phase 2b Development of L...
- Cell Therapeutics : European Marketing Authorizati...
- Allegro Diagnostics : to Develop and Commercialize...
- AstraZeneca : Long-Term SYMBICORT® Use In Children...
- Apieron : FDA Clearance of the Insight™ eNO System...
- Genaera : MedImmune Initiation of Phase 2A Trial o...
- MAP Pharmaceuticals : Positive Results From Compar...
- GlobeImmune, Initiation of a Phase 2a Clinical Tri...
- Tongjitang to Enhance Product Portfolio with a Lea...
- AlphaMed Pharmaceuticals has successfully expresse...
- Universal Detection Technology , Anti-Microbial Pr...
- ArQule, Phase 1/2 Clinical Trial Program of ARQ 19...
- Novelos Therapeutics, Pivotal Phase 3 Lung Cancer ...
- Abbott, Genentech, Roche and OSI, Collaboration on...
- Luminex and Abbott, Agreement for Global Distribut...
- Quidel's QuickVue RSV Test : FDA Grants CLIA Waiver
- Altor BioScience , Tissue Factor Antagonists from ...
- Introgen's p53 Immunotherapy INGN 225 in Patients ...
- Inspire, Second Phase 3 Cystic Fibrosis Trial
- Expression Pathology, Research in Identifying Biom...
- Biothera’s Imprime PGG with Avastin Against Cancer
- Response Genetics, ResponseDX Tests to Select Inst...
- Gilead, Aztreonam Lysine 75 mg Powder for Nebulise...
- Alnylam, First Human Proof of Concept for an RNAi ...
- Aerocrine, NIOX MINO: a New Hand-Held Device to Me...
- KaloBios, Phase 1/2 Trial of KB002 Engineered Mono...
- Cerner and UNMHSC, agreement to evaluate dry-powde...
- Talecris Biotherapeutics, 20th Anniversary of Laun...
- Amira Pharmaceuticals and GSK, global agreement fo...
- Asthmatx, Bronchial Thermoplasty in Refractory Ast...
- Orexo, eoxins, new mechanism for asthma and COPD t...
- Boehringer Ingelheim’s BIBW 2992 for the treatment...
-
▼
March
(46)
Mar 4, 2008
Asthmatx, Bronchial Thermoplasty in Refractory Asthma Results
Sunnyvale, CA, February 11, 2008 – Asthmatx, Inc., a medical device company that has developed a catheter-based procedure under investigation for the treatment of asthma, announced today the publication of data from the Research in Severe Asthma (RISA) Trial of bronchial thermoplasty in the American Journal of Respiratory and Critical Care Medicine (AJRCCM, 2007; 176:1185-1191). The publication reports that despite a transient increase in procedure related adverse events, patients experienced longer term improvement in pulmonary function, improved quality of life and asthma control, and a reduction in rescue medication use for patients treated with bronchial thermoplasty.